Skip to main content

Safety and efficacy of hydroxytyrosol-based formulation on skin inflammation: in vitro evaluation on reconstructed human epidermis model

Abstract

Background

Atopic dermatitis is a multifactorial immune-mediated skin disorder characterized by an alteration of epidermal barrier function and onset of skin lesions, which range from mild erythema to severe lichenification. Treatment consists in hydration with possible use of topical or immunomodulatory corticosteroids, which, however sometimes showed side effects. Recently, the interest in natural compounds has grown significantly and among these, hydroxytyrosol (HT) plays a pivotal role due to its strong and well-known anti-inflammatory activity.

Objectives

The aim of this study was to investigate the safety and efficacy of Fenolia® Eudermal Cream 15 (HT-based formulation) on epidermal barrier impaired as consequence of skin injury.

Methods

Whit this purpose, morphologic and structural as well as anti-inflammatory evaluations, after treatment with pro-inflammatory mediators (PBS 1 X and LPS) and HT-based formulation on reconstructed human epidermis (RHE) were carried out by qualitative (hematoxylin/eosin- and immunostaining) and quantitative (MTT assay, IL-1α and IL-8 release by ELISA) techniques. Furthermore, HT absorption through the epidermal barrier was evaluated by RP-LC-DAD analysis.

Results

A rise in the thickness of the epidermis as well as an appropriate maturation and protein expression (Loricrin, Fillagrin, E-Cadherin and Cytokeratins 5&6) were detected in treated RHE samples. In particular, the HT-based formulation was found to stimulate cell proliferation, as evidenced by the significant increase in Ki67 expression, which suggests the involvement of repair mechanisms, increasing epithelial regeneration and differentiation and improving the epidermal barrier effect. Furthermore, HT-based formulation showed a statistically significant anti-inflammatory activity by reducing both IL-1α and IL-8 release by RHE tissues, greater than the reference drug dexamethasone. Finally, excellent transcutaneous absorption values were found for HT, demonstrating how this new formulation increases the availability of the bioactive compound.

Conclusions

In light of these results, Fenolia® Eudermal Cream 15 could be an effective agent to counteract atopic dermatitis.

Safety and efficacy of hydroxytyrosol-based formulation on skin inflammation: in vitro evaluation on reconstructed human epidermis model

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Abbreviations

AD:

atopic dermatitis

HT:

hydroxytyrosol

PBS:

phosphate buffered saline

MTT:

thiazoyl blue tetrazolium bromide

RP-LC-DAD:

reverse phase-liquid chromatography-diode array detection

RHE:

reconstructed human epidermis

SMM:

skinethic maintenance medium

LPS:

lipopolysaccharides

H&E:

hematoxylin and eosin

RT:

room temperature

Papp :

apparent permeability coefficient

ANOVA:

one-way analysis of variance

SC:

stratum corneum

EVOO:

extra virgin olive oil

References

  1. 1.

    Fabbrocini G, Napolitano M, Megna M, Balato N, Patruno C. Treatment of atopic dermatitis with biologic drugs. Dermatol Ther (Heidelb). 2018. https://doi.org/10.1007/s13555-018-0258-x.

  2. 2.

    Napolitano M, Megna M, Patruno C, Gisondi P, Ayala F, Balato N. Adult atopic dermatitis: a review. G Ital Dermatol Venereol. 2016;151:403–11.

    PubMed  Google Scholar 

  3. 3.

    Katsarou A, Armenaka MC. Atopic dermatitis in older patients: particular points. J Eur Acad Dermatol Venereol. 2011;25:12–8.

    CAS  Article  Google Scholar 

  4. 4.

    Silvestre Salvador JF, Romero-Pérez D, Encabo-Duràn B. Atopic dermatitis in adults: a diagnostic challenge. J Investig Allergol Clin Immunol. 2017;27:78–88.

    CAS  Article  Google Scholar 

  5. 5.

    Dinulos JG, Trickett A, Crudele C. New science and treatment paradigms for atopic dermatitis. Curr Opin Pediatr. 2018;30(1):161–8.

    Article  Google Scholar 

  6. 6.

    Kim DH, Li K, Seo SJ, Jo SJ, Yim HW, Kim CM, et al. Quality of life and disease severity are correlated in patients with atopic dermatitis. J Korean Med Sci. 2012;27:1327–32.

    Article  Google Scholar 

  7. 7.

    Megna M, Napolitano M, Patruno C, Villani A, Balato A, Monfrecola G, et al. Systemic treatment of adult atopic dermatitis: a review. Dermatol Ther (Heidelb). 2017;7:1–23.

    Article  Google Scholar 

  8. 8.

    Calzavara Pinton P, Cristaudo A, Foti C, Canonica GW, Balato N, Costanzo A, et al. Diagnosis and management of moderate to severe adult atopic dermatitis: a consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Italian Association of Hospital Dermatologists (ADOI), the Italian Society of Allergy, asthma and clinical immunology (SIAAIC), and the Italian Society of Allergological, environmental and occupational dermatology (SIDAPA). G Ital Dermatol Venereol. 2018;153(2):133–45.

    PubMed  Google Scholar 

  9. 9.

    Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. European dermatology forum (EDF), the European academy of dermatology and venereology (EADV), the European academy of allergy and clinical immunology (EAACI), the European task force on atopic dermatitis (ETFAD), European Federation of Allergy and Airways Diseases Patients’ associations (EFA), the European Society for Dermatology and Psychiatry (ESDaP), the European Society of Pediatric Dermatology (ESPD), global allergy and asthma European network (GA2LEN) and the European Union of medical specialists (UEMS). Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32:850–78.

    CAS  Article  Google Scholar 

  10. 10.

    Rerknimitr P, Otsuka A, Nakashima C, Kabashima K. The etiopathogenesis of atopic dermatitis: barrier disruption, immunological deragement, and pruritus. Inflamm Regen. 2017;37:14.

    Article  Google Scholar 

  11. 11.

    Megna M, Patruno C, Balato A, Rongioletti F, Stingeni L, Balato N. An Italian multicentre study on adult atopic dermatitis: persistent versus adult-onset disease. Arch Dermatol Res. 2017;309:443–52.

    Article  Google Scholar 

  12. 12.

    Eshtiaghi P, Gooderham MJ. Dupilumab: an evidence- based review of its potential in the treatment of atopic dermatitis. Core Evid. 2018;13:13–20.

    CAS  Article  Google Scholar 

  13. 13.

    Dohil MA. Natural ingredients in atopic dermatitis and other inflammatory skin disease. J Drugs Dermatol. 2013, 12(9):s128–32.

  14. 14.

    Liphschitz N, Gophna R, Hartman M, Biger G. The beginning of olive (Olea europaea) cultivation in the old world: a reassessment. J Arch Sci. 1991;18(4):441–53.

    Article  Google Scholar 

  15. 15.

    Marchetti C, Clericuzio M, Borghesi B, Cornara L, Ribulla S, Gosetti F, et al. Oleuropein-enriched olive leaf extract affects calcium dynamics and impairs viability of malignant mesothelioma cells. Evid Based Complement Alternat Med. 2015;2015:908493.

    Article  Google Scholar 

  16. 16.

    Viola P, Viola M. Virgin olive oil as a fundamental nutritional component and skin protector. Clin Dermatol. 2009;27(2):159–65.

    Article  Google Scholar 

  17. 17.

    Caramia G, Gori A, Valli E, Cerretani L. Virgin olive oil in preventive medicine: from legend to epigenetics. Eur J Lipid Sci Technol. 2012;114:375–88.

    CAS  Article  Google Scholar 

  18. 18.

    Omar SH. Oleuropein in olive and its pharmacological effects. Sci Pharm. 2010;78(2):133–54.

    CAS  Article  Google Scholar 

  19. 19.

    Cicerale S, Lucas L, Keast R. Biological activities of phenolic compounds present in virgin olive oil. Int J Mol Sci. 2010;11(2):458–79.

    CAS  Article  Google Scholar 

  20. 20.

    Trombetta D, Smeriglio A, Marcoccia D, Giofrè SV, Toscano G, Mazzotti F, et al. Analytical evaluation and antioxidant properties of some secondary metabolites in northern Italian mono- and multi-varietal extra virgin olive oils (EVOOs) from early and late harvested olives. Int J Mol Sci. 2017;18(4).

  21. 21.

    Alarcón de la Lastra C, Barranco MD, Motilva V, Herrerías JM. Mediterranean diet and health: biological importance of olive oil. Curr Pharm Des. 2001;7(10):933–50.

    Article  Google Scholar 

  22. 22.

    Colica C, Di Renzo L, Trombetta D, Smeriglio A, Bernardini S, Cioccoloni G, et al. Antioxidant effects of a Hydroxytyrosol-based pharmaceutical formulation on body composition, metabolic state, and gene expression: a randomized double-blinded, placebo-controlled crossover trial. Oxidative Med Cell Longev. 2017;2017:2473495.

    Article  Google Scholar 

  23. 23.

    Martínez L, Ros G, Nieto G. Hydroxytyrosol: health benefits and use as functional ingredient in meat. Medicines (Basel). 2018;5(1):pii E13.

    Article  Google Scholar 

  24. 24.

    Procopio A, Celia C, Nardi M, Oliverio M, Paolino D, Sindona G. Lipophilic hydroxytyrosol esters: fatty acid conjugates for potential topical administration. J Nat Prod. 2011;74:2377–81.

    CAS  Article  Google Scholar 

  25. 25.

    Hussain Z, Katas H, Mohd Amin MC, Kumolosasi E. Efficient immuno-modulation of TH1/TH2 biomarkers in 2,4-dinitrofluorobenzene-induced atopic dermatitis: nanocarrier-mediated transcutaneous co-delivery of anti-inflammatory and antioxidant drugs. PLoS One. 2014;9(11):e113143.

    Article  Google Scholar 

  26. 26.

    Al-Waili NS. Clinical and mycological benefits of topical application of honey, olive oil and beeswax in diaper dermatitis. Clin Microbiol Infect. 2005;11(2):160–3.

    CAS  Article  Google Scholar 

  27. 27.

    Al-Waili NS. Topical application of natural honey, beeswax and olive oil mixture for atopic dermatitis or psoriasis: partially controlled, single-blinded study. Compl Ther Med. 2003;11(4):226–34.

    Article  Google Scholar 

  28. 28.

    Guarrera PM. Usi e Tradizioni della Flora Italiana. Medicina popolare ed etnobotanica. Aracne Editrice S.r.l., Roma; 2006.

  29. 29.

    Smeriglio A, Giovinazzo C, Trombetta D. Development and validation of RP-HPLC-DAD method to quantify hydroxytyrosol content in a semi-solid pharmaceutical formulation. Med Chem. 2015;5:442–6.

    Article  Google Scholar 

  30. 30.

    Lichtenauer M, Nickl S, Hoetzenecker K, Mangold A, Moser B, Zimmermann M, et al. Phosphate buffered saline containing calcium and magnesium elicits increased secretion of Interleukin-1 receptor antagonist. Lab Med. 2009;40(5):290–3.

    Article  Google Scholar 

  31. 31.

    Matabuena-de Yzaguirre M, Bacchini G, Luna EG, Vila-Martínez E. Anti-inflammatory efficacy of product containing “skin calm complex” in vitro reconstructed epidermis. J Cosmet Dermatol Sci Appl. 2014;4:309–15.

    Google Scholar 

  32. 32.

    Gambella A, Porro L, Pigozzi S, Fiocca R, Grillo F, Mastracci L. Section detachment in immunohistochemistry: causes, troubleshooting, and problem-solving. Histochem Cell Biol. 2017;148(1):95–101.

    CAS  Article  Google Scholar 

  33. 33.

    Merlin JL, Azzi S, Lignon D, Ramacci C, Zeghari N. Guillemin F. MTT assays allow quick and reliable measurement of the response of human tumour cells to photodynamic therapy. Eur J Cancer. 1992;28A(8–9):1452–8.

    CAS  Article  Google Scholar 

  34. 34.

    Hussain Z, Katas H, Mohd Amin MC, Kumolosasi E, Buang F, Sahudin S. Self-assembled polymeric nanoparticles for percutaneous co-delivery of hydrocortisone hydroxytyrosol: an ex vivo and in vivo study using an NC/Nga mouse model. Int J Pharm. 2013;444:109–19.

    CAS  Article  Google Scholar 

  35. 35.

    Lias PM, Steinhoff M. “Outside-to-inside” (and now back to “outside”) pathogenic mechanisms in atopic dermatitis. J Invest Dermatol. 2008;128(5):1067–70.

    Article  Google Scholar 

  36. 36.

    Maldonado OS, Lucas R, Comelles F, González MJ, Parra JL, Medina I, et al. Synthesis and characterization of phenolic antioxidants with surfactant properties: glucosyl- and glucuronosyl alkyl gallates. Tetrahedron. 2011;67:7268–79.

    CAS  Article  Google Scholar 

  37. 37.

    Wiechers JW, Kelly CL, Blease TG, Dederen JC. Formulating for efficacy. Int J Cosmet Sci. 2004;26:173–82.

    CAS  Article  Google Scholar 

  38. 38.

    Alonso C, Lucas R, Barba C, Marti M, Rubio L, Comelles F, et al. Skin delivery of antioxidant surfactants based on gallic acid and hydroxytyrosol. J Pharm Pharmacol. 2015;67(7):900–8.

    CAS  Article  Google Scholar 

  39. 39.

    Lee H-J, Lee S-H. Epidermal permeability barrier defects and barrier repair therapy in atopic dermatitis. Allergy Asthma Immunol Res. 2014;6(4):276–87.

    CAS  Article  Google Scholar 

  40. 40.

    Tabassum N, Hamdani M. Plants used to treat skin diseases. Pharmacogn Rev. 2014;8(15):52–60.

    Article  Google Scholar 

  41. 41.

    Shenefelt PD. Herbal treatment for dermatologic disorders. In: Benzie IFF, Wachtel-Galor S, editors. Herbal medicine, 2nd edition biomolecular and clinical aspects. Boca Raton. FL: CRC Press/Taylor & Francis; 2011.

    Google Scholar 

  42. 42.

    Choi NY, Lee JH, Shin HS. Antioxidant activity and nitrite scavenging ability of olive leaf (Olea europaea L.) fractions. Korean J Food Sci Technol. 2008;40:257–64.

    Google Scholar 

  43. 43.

    Fatima PM, Rui C, Susana F, Pedro F, Michael H. Effects of enrichment of refined olive oil with phenolic compounds from olive leaves. J Agric Food Chem. 2007;55:4139–82.

    Article  Google Scholar 

  44. 44.

    Ziogas V, Tanou G, Molassiotis A, Diamantidis G. Antioxidant and free radical-scavenging activities of phenolic extracts of olive fruits. Food Chem. 2010;120:1097–110.

    CAS  Article  Google Scholar 

  45. 45.

    Juráňová J, Franková J, Ulrichová J. The role of keratinocytes in inflammation. J Appl Biomed. 2017;15(3):169–79.

    Article  Google Scholar 

  46. 46.

    Palomo J, Dietrich D, Martin P, Palmer G, Gabay C. The interleukin (IL)-1 cytokine family-balance between agonists and antagonists in inflammatory diseases. Cytokine. 2015;76(1):25–37.

    CAS  Article  Google Scholar 

  47. 47.

    Russo RC, Garcia CC, Teixeira MM, Amaral FA. The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases. Expert Rev Clin Immunol. 2014;10(5):593–619.

    CAS  Article  Google Scholar 

  48. 48.

    Matabuena-de Yzaguirre M, Bacchini G, Vila-Martínez E, Juarranz Á. Product containing “skin calm complex” improves barrier effect in vitro. J Cosmet Dermatol Sci Appl. 2014;4:234–43.

    Google Scholar 

  49. 49.

    Angeloni C, Malaguti M, Barbalace MC, Hrelia S. Bioactivity of olive oil phenols in Neuroprotection. Int J Mol Sci. 2017;18(11):pii E2230.

    Article  Google Scholar 

  50. 50.

    Tutino V, Caruso MG, Messa C, Perri E, Notarnicola M. Antiproliferative, antioxidant and anti-inflammatory effects of hydroxytyrosol on human hepatoma HepG2 and Hep3B cell lines. Anticancer Res. 2012;32(12):5371–7.

    CAS  PubMed  Google Scholar 

  51. 51.

    Jeon S, Choi M. Anti-inflammatory and anti-aging effects of hydroxytyrosol on human dermal fibroblasts (HDFs). Biomed Dermatol. 2018;2:21.

    Article  Google Scholar 

  52. 52.

    Richard N, Arnold S, Hoeller U, Kilpert C, Wertz K, Schwager J. Hydroxytyrosol is the major anti-inflammatory compound in aqueous olive extracts and impairs cytokine and chemokine production in macrophages. Planta Med. 2011;77(17):1890–7.

    CAS  Article  Google Scholar 

  53. 53.

    Killeen MJ, Linder M, Pontoniere P, Crea R. NF-κβ signaling and chronic inflammatory diseases: exploring the potential of natural products to drive new therapeutic opportunities. Drug Discov Today. 2014;19(4):373–8.

    CAS  Article  Google Scholar 

  54. 54.

    Zhang X, Cao J, Jiang L, Zhong L. Suppressive effects of hydroxytyrosol on oxidative stress and nuclear factor-kappaB activation in THP-1 cells. Biol Pharm Bull. 2009;32:578–82.

    CAS  Article  Google Scholar 

  55. 55.

    St-Laurent-Thibault C, Arseneault M, Longpré F, Ramassamy C. Tyrosol and hydroxytyrosol, two main components of olive oil, protect N2a cells against amyloid-b-induced toxicity. Involvement of the NF-kB signaling. Curr Alzheimer Res. 2011;8:543–51.

    CAS  Article  Google Scholar 

  56. 56.

    Huet F, Severino-Freire M, Chéret J, Gouin O, Praneuf J, Pierre O, et al. Reconstructed human epidermis for in vitro studies on atopic dermatitis: a review. J Dermatol Sci. 2018;89(3):213–8.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

The authors thank Simona Pigozzi and Ilaria Tosi for technical support.

Author information

Affiliations

Authors

Contributions

AS and DT designed this study and wrote the manuscript. AS, MD, LM, FG, performed the experiments. LC, SS, SMN and DT analyzed the data and carried out the statistical analysis. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Antonella Smeriglio.

Ethics declarations

Consent for publication

All authors agree to publish the manuscript.

Competing interests

On behalf of all authors, the corresponding author states that there is no conflict of interest.

Ethical approval

Not applicable.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Smeriglio, A., Denaro, M., Mastracci, L. et al. Safety and efficacy of hydroxytyrosol-based formulation on skin inflammation: in vitro evaluation on reconstructed human epidermis model. DARU J Pharm Sci 27, 283–293 (2019). https://doi.org/10.1007/s40199-019-00274-3

Download citation

Keywords

  • Atopic dermatitis
  • Semi-solid formulation
  • Hydroxytyrosol
  • In vitro reconstructed human epidermis
  • Anti-inflammatory effect
  • Histology and immunohistochemistry